Intratumoral N17350 in Advanced Solid Tumors

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop growing in some participants with advanced solid tumors? 2. Are there any side effects for participants when taking N17350? 3. What is the safest dose of N17350 and the dose that should be used for further study? 4. Researchers will give N17350 directly into tumor lesions using a needle (intratumoral i

Trial Details

NCT ID
NCT07339176
Phase
PHASE1 / PHASE2
Sponsor
Onchilles Pharma Inc
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • N17350
Locations (sample)
  • Westmead, New South Wales, Australia|-33.80383,150.98768

Key Eligibility Criteria

  • Age ≥18 years (or legal age of consent in the study jurisdiction).
  • Able to provide written informed consent and willing/able to comply with study procedures, visits, and follow-up.
  • Advanced solid tumor malignancy (excluding lymphoma and other hematologic malignancies), with disease that has progressed on, is intolerant of, or …
  • ECOG performance status 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →